Back to the Top
In order to check the inhibition of CYP 3A4 in vivo, I am planning a =
Midazolam as probe compound. I have several doubts in the design of the =
As the intended route of the drug is neither PO or IV, but there is =
excretion . I am thinking to do the clinical trial only PO =
midazolam, Is all right? I am going to analyze parent Midazolam And the
question is important to analyze 1OH -Midazolam?
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Midazolam DDI Design" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (firstname.lastname@example.org)